ID   CANT1_HUMAN             Reviewed;         401 AA.
AC   Q8WVQ1; B4DJ54; Q7Z2J7; Q8NG05; Q8NHP0; Q9BSD5;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   10-MAY-2017, entry version 133.
DE   RecName: Full=Soluble calcium-activated nucleotidase 1;
DE            Short=SCAN-1;
DE            EC=3.6.1.6 {ECO:0000269|PubMed:12234496, ECO:0000269|PubMed:15006348, ECO:0000269|PubMed:15248776, ECO:0000269|PubMed:16835225};
DE   AltName: Full=Apyrase homolog;
DE   AltName: Full=Putative MAPK-activating protein PM09;
DE   AltName: Full=Putative NF-kappa-B-activating protein 107;
GN   Name=CANT1; Synonyms=SHAPY;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, SUBUNIT, SUBCELLULAR LOCATION, GLYCOSYLATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Mammary tumor;
RX   PubMed=12234496; DOI=10.1016/S0003-9861(02)00420-4;
RA   Smith T., Hicks-Berger C., Kim S., Kirley T.;
RT   "Cloning, expression, and characterization of a soluble calcium-
RT   activated nucleotidase, a human enzyme belonging to a new family of
RT   extracellular nucleotidases.";
RL   Arch. Biochem. Biophys. 406:105-115(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lung fibroblast;
RX   PubMed=12761501; DOI=10.1038/sj.onc.1206406;
RA   Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O.,
RA   Nagano Y., Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H.,
RA   Sugano S.;
RT   "Large-scale identification and characterization of human genes that
RT   activate NF-kappaB and MAPK signaling pathways.";
RL   Oncogene 22:3307-3318(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Mammary gland, and Substantia nigra;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary, Pancreas, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 141-401 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=12167635; DOI=10.1074/jbc.M201656200;
RA   Failer B.U., Braun N., Zimmermann H.;
RT   "Cloning, expression, and functional characterization of a Ca2+-
RT   dependent endoplasmic reticulum nucleoside diphosphatase.";
RL   J. Biol. Chem. 277:36978-36986(2002).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND MUTAGENESIS OF ASP-114;
RP   GLY-152; GLU-160; ARG-163; ASP-181; ASP-205 AND ARG-301.
RX   PubMed=15248776; DOI=10.1021/bi049565o;
RA   Yang M., Kirley T.L.;
RT   "Site-directed mutagenesis of human soluble calcium-activated
RT   nucleotidase 1 (hSCAN-1): identification of residues essential for
RT   enzyme activity and the Ca(2+)-induced conformational change.";
RL   Biochemistry 43:9185-9194(2004).
RN   [7]
RP   INVOLVEMENT IN DBQD1.
RX   PubMed=20425819; DOI=10.1002/ajmg.a.33404;
RA   Faden M., Al-Zahrani F., Arafah D., Alkuraya F.S.;
RT   "Mutation of CANT1 causes Desbuquois dysplasia.";
RL   Am. J. Med. Genet. A 152:1157-1160(2010).
RN   [8]
RP   FUNCTION IN PROTEOGLYCAN SYNTHESIS, AND VARIANTS DBQD1 HIS-300;
RP   ARG-303 AND ASN-374.
RX   PubMed=22539336; DOI=10.1002/humu.22104;
RA   Nizon M., Huber C., De Leonardis F., Merrina R., Forlino A.,
RA   Fradin M., Tuysuz B., Abu-Libdeh B.Y., Alanay Y., Albrecht B.,
RA   Al-Gazali L., Basaran S.Y., Clayton-Smith J., Desir J., Gill H.,
RA   Greally M.T., Koparir E., van Maarle M.C., Mackay S., Mortier G.,
RA   Morton J., Sillence D., Vilain C., Young I., Zerres K., Le Merrer M.,
RA   Munnich A., Le Goff C., Rossi A., Cormier-Daire V.;
RT   "Further delineation of CANT1 phenotypic spectrum and demonstration of
RT   its role in proteoglycan synthesis.";
RL   Hum. Mutat. 33:1261-1266(2012).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 71-401 IN COMPLEX WITH
RP   SUBSTRATE ANALOG AND CALCIUM IONS, CATALYTIC ACTIVITY, COFACTOR,
RP   SUBUNIT, AND MUTAGENESIS OF ASP-112; ASP-114; GLU-166; SER-168;
RP   ASP-169; ASP-182; GLU-215; GLU-246 AND ARG-301.
RX   PubMed=15006348; DOI=10.1016/S0092-8674(04)00172-2;
RA   Dai J., Liu J., Deng Y., Smith T.M., Lu M.;
RT   "Structure and protein design of a human platelet function
RT   inhibitor.";
RL   Cell 116:649-659(2004).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 69-401 IN COMPLEX WITH
RP   CALCIUM, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, DIMERIZATION,
RP   SUBCELLULAR LOCATION, DISULFIDE BOND, AND MUTAGENESIS OF CYS-60;
RP   SER-139; GLU-160; ILE-200; SER-202; SER-256; CYS-287; SER-308 AND
RP   ALA-317.
RX   PubMed=16835225; DOI=10.1074/jbc.M604413200;
RA   Yang M., Horii K., Herr A.B., Kirley T.L.;
RT   "Calcium-dependent dimerization of human soluble calcium activated
RT   nucleotidase: characterization of the dimer interface.";
RL   J. Biol. Chem. 281:28307-28317(2006).
RN   [11]
RP   VARIANTS DBQD1 LEU-299; CYS-300 AND HIS-300.
RX   PubMed=19853239; DOI=10.1016/j.ajhg.2009.10.001;
RA   Huber C., Oules B., Bertoli M., Chami M., Fradin M., Alanay Y.,
RA   Al-Gazali L.I., Ausems M.G., Bitoun P., Cavalcanti D.P., Krebs A.,
RA   Le Merrer M., Mortier G., Shafeghati Y., Superti-Furga A.,
RA   Robertson S.P., Le Goff C., Muda A.O., Paterlini-Brechot P.,
RA   Munnich A., Cormier-Daire V.;
RT   "Identification of CANT1 mutations in Desbuquois dysplasia.";
RL   Am. J. Hum. Genet. 85:706-710(2009).
RN   [12]
RP   VARIANT DBQD1 GLU-112.
RX   PubMed=21654728; DOI=10.1038/ejhg.2011.101;
RA   Laccone F., Schoner K., Krabichler B., Kluge B., Schwerdtfeger R.,
RA   Schulze B., Zschocke J., Rehder H.;
RT   "Desbuquois dysplasia type I and fetal hydrops due to novel mutations
RT   in the CANT1 gene.";
RL   Eur. J. Hum. Genet. 19:1133-1137(2011).
RN   [13]
RP   VARIANT DBQD1 MET-226.
RX   PubMed=21412251; DOI=10.1038/jhg.2011.28;
RA   Dai J., Kim O.H., Cho T.J., Miyake N., Song H.R., Karasugi T.,
RA   Sakazume S., Ikema M., Matsui Y., Nagai T., Matsumoto N., Ohashi H.,
RA   Kamatani N., Nishimura G., Furuichi T., Takahashi A., Ikegawa S.;
RT   "A founder mutation of CANT1 common in Korean and Japanese Desbuquois
RT   dysplasia.";
RL   J. Hum. Genet. 56:398-400(2011).
RN   [14]
RP   VARIANTS DBQD1 CYS-125; THR-165; PRO-224; MET-226 AND ASP-360,
RP   CHARACTERIZATION OF VARIANTS DBQD1 CYS-125; THR-165; PRO-224; MET-226;
RP   CYS-300 AND ASP-360, AND CHARACTERIZATION OF VARIANTS THR-323 AND
RP   GLU-391.
RX   PubMed=21037275; DOI=10.1136/jmg.2010.080226;
RA   Furuichi T., Dai J., Cho T.J., Sakazume S., Ikema M., Matsui Y.,
RA   Baynam G., Nagai T., Miyake N., Matsumoto N., Ohashi H., Unger S.,
RA   Superti-Furga A., Kim O.H., Nishimura G., Ikegawa S.;
RT   "CANT1 mutation is also responsible for Desbuquois dysplasia, type 2
RT   and Kim variant.";
RL   J. Med. Genet. 48:32-37(2011).
CC   -!- FUNCTION: Calcium-dependent nucleotidase with a preference for
CC       UDP. The order of activity with different substrates is UDP > GDP
CC       > UTP > GTP. Has very low activity towards ADP and even lower
CC       activity towards ATP. Does not hydrolyze AMP and GMP
CC       (PubMed:12234496, PubMed:15248776, PubMed:15006348,
CC       PubMed:16835225). Involved in proteoglycan synthesis
CC       (PubMed:22539336). {ECO:0000269|PubMed:12234496,
CC       ECO:0000269|PubMed:15006348, ECO:0000269|PubMed:15248776,
CC       ECO:0000269|PubMed:16835225, ECO:0000269|PubMed:22539336}.
CC   -!- CATALYTIC ACTIVITY: A nucleoside diphosphate + H(2)O = a
CC       nucleoside phosphate + phosphate. {ECO:0000269|PubMed:12234496,
CC       ECO:0000269|PubMed:15248776, ECO:0000269|PubMed:16835225}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:12234496,
CC         ECO:0000269|PubMed:15006348, ECO:0000269|PubMed:15248776,
CC         ECO:0000269|PubMed:16835225};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 6.8.;
CC   -!- SUBUNIT: Monomer (PubMed:12234496, PubMed:15006348). Homodimer;
CC       dimerization is Ca(2+)-dependent (PubMed:16835225). Homodimer;
CC       disulfide-linked (membrane form) (PubMed:16835225).
CC       {ECO:0000269|PubMed:12234496, ECO:0000269|PubMed:15006348,
CC       ECO:0000269|PubMed:16835225}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:12234496}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:12234496}. Golgi apparatus, Golgi
CC       stack membrane {ECO:0000269|PubMed:12234496}; Single-pass type II
CC       membrane protein {ECO:0000269|PubMed:12234496}. Cell membrane
CC       {ECO:0000269|PubMed:16835225}. Note=Processed form: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8WVQ1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WVQ1-2; Sequence=VSP_013760, VSP_013761;
CC       Name=3;
CC         IsoId=Q8WVQ1-3; Sequence=VSP_054260;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:12234496}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12234496}.
CC   -!- DISEASE: Desbuquois dysplasia 1 (DBQD1) [MIM:251450]: A
CC       chondrodysplasia characterized by severe prenatal and postnatal
CC       growth retardation (less than -5 SD), joint laxity, short
CC       extremities, progressive scoliosis, round face, midface
CC       hypoplasia, prominent bulging eyes. The main radiologic features
CC       are short long bones with metaphyseal splay, a 'Swedish key'
CC       appearance of the proximal femur (exaggerated trochanter), and
CC       advance carpal and tarsal bone age. Two forms of Desbuquois
CC       dysplasia are distinguished on the basis of the presence or
CC       absence of characteristic hand anomalies: an extra ossification
CC       center distal to the second metacarpal, delta phalanx, bifid
CC       distal thumb phalanx, and phalangeal dislocations.
CC       {ECO:0000269|PubMed:19853239, ECO:0000269|PubMed:20425819,
CC       ECO:0000269|PubMed:21037275, ECO:0000269|PubMed:21412251,
CC       ECO:0000269|PubMed:21654728, ECO:0000269|PubMed:22539336}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Not inhibited by azide.
CC   -!- SIMILARITY: Belongs to the apyrase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAM94564.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF328554; AAM94564.1; ALT_INIT; mRNA.
DR   EMBL; AB097006; BAC77359.1; -; mRNA.
DR   EMBL; AB097033; BAC77386.1; -; mRNA.
DR   EMBL; AK074687; BAC11139.1; -; mRNA.
DR   EMBL; AK295930; BAG58716.1; -; mRNA.
DR   EMBL; BC005104; AAH05104.1; -; mRNA.
DR   EMBL; BC017655; AAH17655.1; -; mRNA.
DR   EMBL; BC065038; AAH65038.1; -; mRNA.
DR   EMBL; AJ312208; CAC85468.1; -; mRNA.
DR   CCDS; CCDS11760.1; -. [Q8WVQ1-1]
DR   RefSeq; NP_001153244.1; NM_001159772.1. [Q8WVQ1-1]
DR   RefSeq; NP_001153245.1; NM_001159773.1. [Q8WVQ1-1]
DR   RefSeq; NP_620148.1; NM_138793.3. [Q8WVQ1-1]
DR   RefSeq; XP_005257078.1; XM_005257021.1. [Q8WVQ1-1]
DR   RefSeq; XP_005257079.1; XM_005257022.1. [Q8WVQ1-1]
DR   RefSeq; XP_006721746.1; XM_006721683.1. [Q8WVQ1-1]
DR   RefSeq; XP_011522593.1; XM_011524291.1. [Q8WVQ1-1]
DR   RefSeq; XP_011522595.1; XM_011524293.1. [Q8WVQ1-1]
DR   RefSeq; XP_011522596.1; XM_011524294.1. [Q8WVQ1-1]
DR   RefSeq; XP_011522597.1; XM_011524295.2. [Q8WVQ1-1]
DR   UniGene; Hs.8859; -.
DR   PDB; 1S18; X-ray; 1.70 A; A/B=71-401.
DR   PDB; 1S1D; X-ray; 1.60 A; A/B=71-401.
DR   PDB; 2H2N; X-ray; 2.30 A; A/B=69-401.
DR   PDB; 2H2U; X-ray; 2.40 A; A/B=69-401.
DR   PDBsum; 1S18; -.
DR   PDBsum; 1S1D; -.
DR   PDBsum; 2H2N; -.
DR   PDBsum; 2H2U; -.
DR   ProteinModelPortal; Q8WVQ1; -.
DR   SMR; Q8WVQ1; -.
DR   BioGrid; 125875; 16.
DR   STRING; 9606.ENSP00000307674; -.
DR   DrugBank; DB03486; Phosphomethylphosphonic Acid Guanosyl Ester.
DR   DrugBank; DB03754; Tris.
DR   iPTMnet; Q8WVQ1; -.
DR   PhosphoSitePlus; Q8WVQ1; -.
DR   BioMuta; CANT1; -.
DR   DMDM; 66774052; -.
DR   EPD; Q8WVQ1; -.
DR   MaxQB; Q8WVQ1; -.
DR   PaxDb; Q8WVQ1; -.
DR   PeptideAtlas; Q8WVQ1; -.
DR   PRIDE; Q8WVQ1; -.
DR   Ensembl; ENST00000302345; ENSP00000307674; ENSG00000171302. [Q8WVQ1-1]
DR   Ensembl; ENST00000392446; ENSP00000376241; ENSG00000171302. [Q8WVQ1-1]
DR   Ensembl; ENST00000591773; ENSP00000467437; ENSG00000171302. [Q8WVQ1-1]
DR   Ensembl; ENST00000620915; ENSP00000477798; ENSG00000171302. [Q8WVQ1-1]
DR   GeneID; 124583; -.
DR   KEGG; hsa:124583; -.
DR   UCSC; uc002jwj.4; human. [Q8WVQ1-1]
DR   CTD; 124583; -.
DR   DisGeNET; 124583; -.
DR   GeneCards; CANT1; -.
DR   HGNC; HGNC:19721; CANT1.
DR   HPA; HPA019627; -.
DR   HPA; HPA019639; -.
DR   HPA; HPA022818; -.
DR   MalaCards; CANT1; -.
DR   MIM; 251450; phenotype.
DR   MIM; 613165; gene.
DR   neXtProt; NX_Q8WVQ1; -.
DR   OpenTargets; ENSG00000171302; -.
DR   Orphanet; 1425; Desbuquois syndrome.
DR   PharmGKB; PA134984439; -.
DR   eggNOG; KOG4494; Eukaryota.
DR   eggNOG; ENOG410XS4T; LUCA.
DR   GeneTree; ENSGT00390000012872; -.
DR   HOGENOM; HOG000008129; -.
DR   HOVERGEN; HBG059824; -.
DR   InParanoid; Q8WVQ1; -.
DR   KO; K12304; -.
DR   OMA; VVPTHGF; -.
DR   OrthoDB; EOG091G0DL5; -.
DR   PhylomeDB; Q8WVQ1; -.
DR   TreeFam; TF315248; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   ChiTaRS; CANT1; human.
DR   EvolutionaryTrace; Q8WVQ1; -.
DR   GeneWiki; CANT1; -.
DR   GenomeRNAi; 124583; -.
DR   PRO; PR:Q8WVQ1; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000171302; -.
DR   CleanEx; HS_CANT1; -.
DR   ExpressionAtlas; Q8WVQ1; baseline and differential.
DR   Genevisible; Q8WVQ1; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0043262; F:adenosine-diphosphatase activity; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004382; F:guanosine-diphosphatase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IMP:UniProtKB.
DR   GO; GO:0045134; F:uridine-diphosphatase activity; IBA:GO_Central.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; IMP:UniProtKB.
DR   InterPro; IPR009283; Apyrase.
DR   PANTHER; PTHR13023; PTHR13023; 1.
DR   Pfam; PF06079; Apyrase; 1.
DR   SUPFAM; SSF101887; SSF101887; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Dwarfism;
KW   Endoplasmic reticulum; Glycoprotein; Golgi apparatus; Hydrolase;
KW   Membrane; Metal-binding; Polymorphism; Reference proteome;
KW   Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN         1    401       Soluble calcium-activated nucleotidase 1.
FT                                /FTId=PRO_0000209925.
FT   TOPO_DOM      1     44       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     45     62       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     63    401       Lumenal. {ECO:0000255}.
FT   METAL       168    168       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1S18,
FT                                ECO:0000244|PDB:1S1D,
FT                                ECO:0000244|PDB:2H2N,
FT                                ECO:0000244|PDB:2H2U,
FT                                ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:16835225}.
FT   METAL       169    169       Calcium. {ECO:0000244|PDB:1S18,
FT                                ECO:0000244|PDB:2H2N,
FT                                ECO:0000244|PDB:2H2U,
FT                                ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:16835225}.
FT   METAL       215    215       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1S18,
FT                                ECO:0000244|PDB:1S1D,
FT                                ECO:0000244|PDB:2H2N,
FT                                ECO:0000244|PDB:2H2U,
FT                                ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:16835225}.
FT   METAL       284    284       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1S18,
FT                                ECO:0000244|PDB:1S1D,
FT                                ECO:0000244|PDB:2H2N,
FT                                ECO:0000244|PDB:2H2U,
FT                                ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:16835225}.
FT   METAL       345    345       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1S18,
FT                                ECO:0000244|PDB:1S1D,
FT                                ECO:0000244|PDB:2H2N,
FT                                ECO:0000244|PDB:2H2U,
FT                                ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:16835225}.
FT   METAL       396    396       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1S18,
FT                                ECO:0000244|PDB:1S1D,
FT                                ECO:0000244|PDB:2H2N,
FT                                ECO:0000244|PDB:2H2U,
FT                                ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:16835225}.
FT   SITE        160    160       Important for dimer formation.
FT                                {ECO:0000269|PubMed:16835225}.
FT   SITE        200    200       Important for dimer formation.
FT                                {ECO:0000269|PubMed:16835225}.
FT   SITE        202    202       Important for dimer formation.
FT                                {ECO:0000269|PubMed:16835225}.
FT   SITE        256    256       Important for dimer formation.
FT                                {ECO:0000269|PubMed:16835225}.
FT   CARBOHYD     88     88       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     60     60       Interchain.
FT                                {ECO:0000269|PubMed:16835225}.
FT   VAR_SEQ      41     91       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054260.
FT   VAR_SEQ     220    245       KDERLYVGGLGKEWTTTTGDVVNENP -> REIVRKRWRLV
FT                                KQVSHVGVLGQWIQR (in isoform 2).
FT                                {ECO:0000303|PubMed:12761501}.
FT                                /FTId=VSP_013760.
FT   VAR_SEQ     246    401       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12761501}.
FT                                /FTId=VSP_013761.
FT   VARIANT     112    112       D -> E (in DBQD1; dbSNP:rs749246739).
FT                                {ECO:0000269|PubMed:21654728}.
FT                                /FTId=VAR_068655.
FT   VARIANT     125    125       W -> C (in DBQD1; severely affects
FT                                activity; dbSNP:rs587776898).
FT                                {ECO:0000269|PubMed:21037275}.
FT                                /FTId=VAR_068656.
FT   VARIANT     165    165       M -> T (in DBQD1; severely affects
FT                                activity). {ECO:0000269|PubMed:21037275}.
FT                                /FTId=VAR_068657.
FT   VARIANT     224    224       L -> P (in DBQD1; affects protein
FT                                stability and secretion;
FT                                dbSNP:rs150181226).
FT                                {ECO:0000269|PubMed:21037275}.
FT                                /FTId=VAR_068658.
FT   VARIANT     226    226       V -> M (in DBQD1; severely affects
FT                                activity; dbSNP:rs377546036).
FT                                {ECO:0000269|PubMed:21037275,
FT                                ECO:0000269|PubMed:21412251}.
FT                                /FTId=VAR_068659.
FT   VARIANT     299    299       P -> L (in DBQD1; dbSNP:rs267606700).
FT                                {ECO:0000269|PubMed:19853239}.
FT                                /FTId=VAR_062980.
FT   VARIANT     300    300       R -> C (in DBQD1; severely affects
FT                                activity; dbSNP:rs267606701).
FT                                {ECO:0000269|PubMed:19853239,
FT                                ECO:0000269|PubMed:21037275}.
FT                                /FTId=VAR_062981.
FT   VARIANT     300    300       R -> H (in DBQD1; dbSNP:rs267606699).
FT                                {ECO:0000269|PubMed:19853239,
FT                                ECO:0000269|PubMed:22539336}.
FT                                /FTId=VAR_062982.
FT   VARIANT     303    303       S -> R (in DBQD1).
FT                                {ECO:0000269|PubMed:22539336}.
FT                                /FTId=VAR_068660.
FT   VARIANT     323    323       A -> T (polymorphism; does not affect
FT                                activity; dbSNP:rs9903215).
FT                                {ECO:0000269|PubMed:21037275}.
FT                                /FTId=VAR_068661.
FT   VARIANT     360    360       A -> D (in DBQD1; affects protein
FT                                secretion; dbSNP:rs387907081).
FT                                {ECO:0000269|PubMed:21037275}.
FT                                /FTId=VAR_068662.
FT   VARIANT     374    374       I -> N (in DBQD1).
FT                                {ECO:0000269|PubMed:22539336}.
FT                                /FTId=VAR_068663.
FT   VARIANT     391    391       G -> E (polymorphism; does not affect
FT                                activity; dbSNP:rs34082669).
FT                                {ECO:0000269|PubMed:21037275}.
FT                                /FTId=VAR_068664.
FT   MUTAGEN      60     60       C->S: Loss of dimer formation.
FT                                {ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     112    112       D->A: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:15006348}.
FT   MUTAGEN     114    114       D->A: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:15248776}.
FT   MUTAGEN     139    139       S->C: Reduces GDPase and ADPase
FT                                activities 1.7-fold. Severe loss of dimer
FT                                formation; when associated with S-287.
FT                                {ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     152    152       G->E: Slightly reduced activity.
FT                                {ECO:0000269|PubMed:15248776}.
FT   MUTAGEN     160    160       E->Y: Increases GDPase activity 2-fold
FT                                and ADPase activity 5-fold. Forms dimer
FT                                even at suboptimal Ca(2+) concentrations.
FT                                {ECO:0000269|PubMed:15248776,
FT                                ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     163    163       R->A: Reduces activity by 98%.
FT                                {ECO:0000269|PubMed:15248776}.
FT   MUTAGEN     166    166       E->Q: Reduces activity by 95%.
FT                                {ECO:0000269|PubMed:15006348}.
FT   MUTAGEN     168    168       S->A: Reduces activity by over 99.9%.
FT                                {ECO:0000269|PubMed:15006348}.
FT   MUTAGEN     169    169       D->N: Reduces activity by 96%.
FT                                {ECO:0000269|PubMed:15006348}.
FT   MUTAGEN     181    181       D->A: Loss of activity.
FT                                {ECO:0000269|PubMed:15248776}.
FT   MUTAGEN     182    182       D->N: Reduces activity by over 99.9%.
FT                                {ECO:0000269|PubMed:15006348}.
FT   MUTAGEN     200    200       I->C: Reduces GDPase activity 2-fold and
FT                                ADPase activity 2.5-fold. No effect on
FT                                dimer formation; when associated with S-
FT                                287. {ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     202    202       S->C: Reduces GDPase activity 1.7-fold
FT                                and ADPase activity 1.5-fold. No effect
FT                                on dimer formation; when associated with
FT                                S-287. {ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     205    205       D->A: Slightly reduced activity.
FT                                {ECO:0000269|PubMed:15248776}.
FT   MUTAGEN     215    215       E->Q: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:15006348}.
FT   MUTAGEN     246    246       E->M: Increases activity 5-fold.
FT                                {ECO:0000269|PubMed:15006348}.
FT   MUTAGEN     256    256       S->C: No effect on GDPase and ADPase
FT                                activities. No effect on dimer formation;
FT                                when associated with S-287.
FT                                {ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     287    287       C->S: Reduces GDPase and ADPase
FT                                activities 1.3-fold.
FT                                {ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     301    301       R->A: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:15006348,
FT                                ECO:0000269|PubMed:15248776}.
FT   MUTAGEN     308    308       S->C: Reduces GDPase activity 1.3-fold
FT                                and ADPase activity 2-fold. Severe loss
FT                                of dimer formation; when associated with
FT                                S-287. {ECO:0000269|PubMed:16835225}.
FT   MUTAGEN     317    317       A->C: Reduces GDPase activity 1.7-fold
FT                                and ADPase activity 1.5-fold. Severe loss
FT                                of dimer formation; when associated with
FT                                S-287. {ECO:0000269|PubMed:16835225}.
FT   STRAND       92     94       {ECO:0000244|PDB:1S1D}.
FT   STRAND       97     99       {ECO:0000244|PDB:1S1D}.
FT   STRAND      102    112       {ECO:0000244|PDB:1S1D}.
FT   HELIX       114    117       {ECO:0000244|PDB:1S1D}.
FT   STRAND      125    137       {ECO:0000244|PDB:1S1D}.
FT   STRAND      143    147       {ECO:0000244|PDB:1S1D}.
FT   STRAND      152    157       {ECO:0000244|PDB:1S1D}.
FT   STRAND      158    160       {ECO:0000244|PDB:2H2U}.
FT   STRAND      167    173       {ECO:0000244|PDB:1S1D}.
FT   STRAND      176    181       {ECO:0000244|PDB:1S1D}.
FT   TURN        182    184       {ECO:0000244|PDB:1S1D}.
FT   STRAND      186    191       {ECO:0000244|PDB:1S1D}.
FT   STRAND      194    200       {ECO:0000244|PDB:1S1D}.
FT   TURN        204    207       {ECO:0000244|PDB:1S1D}.
FT   STRAND      208    211       {ECO:0000244|PDB:1S1D}.
FT   STRAND      216    220       {ECO:0000244|PDB:1S1D}.
FT   STRAND      223    227       {ECO:0000244|PDB:1S1D}.
FT   STRAND      240    242       {ECO:0000244|PDB:1S1D}.
FT   HELIX       244    246       {ECO:0000244|PDB:1S1D}.
FT   STRAND      247    251       {ECO:0000244|PDB:1S1D}.
FT   STRAND      257    261       {ECO:0000244|PDB:1S1D}.
FT   HELIX       263    272       {ECO:0000244|PDB:1S1D}.
FT   STRAND      280    282       {ECO:0000244|PDB:1S1D}.
FT   STRAND      286    289       {ECO:0000244|PDB:1S1D}.
FT   TURN        290    293       {ECO:0000244|PDB:1S1D}.
FT   STRAND      294    297       {ECO:0000244|PDB:1S1D}.
FT   STRAND      300    305       {ECO:0000244|PDB:1S1D}.
FT   HELIX       309    312       {ECO:0000244|PDB:1S1D}.
FT   STRAND      319    323       {ECO:0000244|PDB:1S1D}.
FT   STRAND      330    334       {ECO:0000244|PDB:1S1D}.
FT   STRAND      342    349       {ECO:0000244|PDB:1S1D}.
FT   STRAND      357    366       {ECO:0000244|PDB:1S1D}.
FT   STRAND      369    378       {ECO:0000244|PDB:1S1D}.
FT   STRAND      383    400       {ECO:0000244|PDB:1S1D}.
SQ   SEQUENCE   401 AA;  44840 MW;  5B78EB24C0B2C4CA CRC64;
     MPVQLSEHPE WNESMHSLRI SVGGLPVLAS MTKAADPRFR PRWKVILTFF VGAAILWLLC
     SHRPAPGRPP THNAHNWRLG QAPANWYNDT YPLSPPQRTP AGIRYRIAVI ADLDTESRAQ
     EENTWFSYLK KGYLTLSDSG DKVAVEWDKD HGVLESHLAE KGRGMELSDL IVFNGKLYSV
     DDRTGVVYQI EGSKAVPWVI LSDGDGTVEK GFKAEWLAVK DERLYVGGLG KEWTTTTGDV
     VNENPEWVKV VGYKGSVDHE NWVSNYNALR AAAGIQPPGY LIHESACWSD TLQRWFFLPR
     RASQERYSEK DDERKGANLL LSASPDFGDI AVSHVGAVVP THGFSSFKFI PNTDDQIIVA
     LKSEEDSGRV ASYIMAFTLD GRFLLPETKI GSVKYEGIEF I
//
